Speaker Credentials
OMS-II
Speaker Credentials
BS
College
Dr. Kiran C. Patel College of Osteopathic Medicine, DO
Medical Specialty
Cardiology
Format
Poster
Start Date
November 2024
End Date
November 2024
Track
3
Abstract
Objective: This literature review aims to investigate recent developments in tirzepatide’s ability to lessen CVD risk factors for adults with increased risk of major adverse cardiovascular events. Background: Tirzepatide is an FDA - approved medication primarily used to treat adults with type 2 diabetes mellitus (T2DM) by reducing A1C and chronic weight management, however its efficacy for reducing CVD risk factors is under examination. Methods: This review synthesizes data from recent early findings published by the pharmaceutical company, which has not yet undergone peer review, alongside existing literature on tirzepatide. Additional sources were identified through a systematic search of PubMed, Google Scholar, and clinical trial registries using the keywords cardiovascular events, and tirzepatide. Results: Clinical study (NCT04847557) found that 5 mg, 10 mg, and 15 mg injections of tirzepatide in adults with HFpEF and obesity lessened the probability of heart failure hospitalizations or urgent care visits, diuretic intensification, and CV death when compared to placebo. All doses of tirzepatide decreased hsCRP in participants, an inflammatory marker indicated in CVD risk. In vitro analysis of tirzepatide’s effect on cardiac remodeling showed that AC16 cell lines treated with tirzepatide within an elevated glucose environment showed protective cardiac effect inhibiting fibrosis, cell death, and hypertrophy compared to AC16 cells without tirzepatide. Conclusion: Early findings suggest the efficacy of tirzepatide for the treatment of adults with increased cardiovascular risk. The results of the ongoing clinical trial NCT04255433 will offer additional insight regarding tirzepatide’s effect on reducing major adverse cardiovascular events in adults with T2DM.
Included in
Cardiology Commons, Medical Pharmacology Commons, Pharmacy and Pharmaceutical Sciences Commons
Recent Developments in Tirzepatide's Role in Reducing Cardiovascular Disease Risk Factors in Adults with Type 2 Diabetes
Objective: This literature review aims to investigate recent developments in tirzepatide’s ability to lessen CVD risk factors for adults with increased risk of major adverse cardiovascular events. Background: Tirzepatide is an FDA - approved medication primarily used to treat adults with type 2 diabetes mellitus (T2DM) by reducing A1C and chronic weight management, however its efficacy for reducing CVD risk factors is under examination. Methods: This review synthesizes data from recent early findings published by the pharmaceutical company, which has not yet undergone peer review, alongside existing literature on tirzepatide. Additional sources were identified through a systematic search of PubMed, Google Scholar, and clinical trial registries using the keywords cardiovascular events, and tirzepatide. Results: Clinical study (NCT04847557) found that 5 mg, 10 mg, and 15 mg injections of tirzepatide in adults with HFpEF and obesity lessened the probability of heart failure hospitalizations or urgent care visits, diuretic intensification, and CV death when compared to placebo. All doses of tirzepatide decreased hsCRP in participants, an inflammatory marker indicated in CVD risk. In vitro analysis of tirzepatide’s effect on cardiac remodeling showed that AC16 cell lines treated with tirzepatide within an elevated glucose environment showed protective cardiac effect inhibiting fibrosis, cell death, and hypertrophy compared to AC16 cells without tirzepatide. Conclusion: Early findings suggest the efficacy of tirzepatide for the treatment of adults with increased cardiovascular risk. The results of the ongoing clinical trial NCT04255433 will offer additional insight regarding tirzepatide’s effect on reducing major adverse cardiovascular events in adults with T2DM.